Amgen Inc at Credit Suisse Healthcare Conference Transcript

Nov 09, 2022 / 08:50PM GMT
Matthew Weston - Crédit Suisse AG - Research Division - MD and Co-Head of European Pharmaceutical Equity Research

Good afternoon, everyone. The company is represented by Peter Griffith, CFO and Dave Reese, EVP of R&D. My name is Matthew Weston. For those of you who don't know me, I cover European therapeutics for Credit Suisse.

Gentlemen, thank you so much for joining us. And I think you want to make a few opening comments before we jump in with the discussion.

Peter H. Griffith - Amgen Inc. - Executive VP & CFO

Great. Matt, thank you, and thank you, Credit Suisse. We're delighted to be here.

So I'd just like to give you a couple of thoughts. The third quarter was another quarter of solid execution for Amgen despite the macro headwinds that we're all facing out there that reflected volume-driven growth. In the inflamm portfolio, our TEZSPIRE launch continues to be strong and moving ahead for patients with severe asthma. We closed the acquisition of ChemoCentryx recently. Great deployment of our shareholders'

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
4.6 out of 5 Trustpilot